The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Two-Year US Pharmacovigilance Report on Brodalumab
Open accessAbstract
INTRODUCTION: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the United States, brodalumab carries a boxed warning about suicidal ideation and behavior; however, no causal association was established between brodalumab and suicides reported during pivotal trials. We have previously reported results from an analysis of 1-year pharmacovigilance data in patients in the United States who took brodalumab, in which the most commonly reported adverse event was psoriasis flare. There were no completed suicides, suicide attempts, or serious fungal infections. Here, we provide a 2-year US pharmacovigilance report. METHODS: This analysis summarizes pharmacovigilance data reported to Ortho Dermatologics by US patients and healthcare providers from August 15, 2017, through August 14, 2019. The most common adverse events listed in the brodalumab package insert (incidence ≥ 1%; arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection-site reactions, influenza, neutropenia, and tinea infections) and adverse events of special interest are reported. RESULTS: Data were collected from 2677 patients in the United States who took brodalumab, with an estimated exposure of 1656 patient-years. Arthralgia was the most commonly reported adverse event (73 events; 0.04 events per patient-year). No suicide attempts or completed suicides were reported; there were 25 reports of depression. There were 46 serious infections and no serious fungal infections. One event of Crohn's disease was reported, which led to discontinuation. There were 13 malignancies, with none deemed related to brodalumab. CONCLUSIONS: This pharmacovigilance report supports the safety profile of brodalumab previously reported from long-term analyses of clinical trials and 1-year pharmacovigilance data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 941
Self-citationPhase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Self-citationPapp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14493 · Cited by 470
Psoriasis: Which therapy for which patient
Kaushik, S. B., & Lebwohl, M. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.057 · Cited by 368
Self-citationBlauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
Psoriasis: Which therapy for which patient
Kaushik, S. B., & Lebwohl, M. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.056 · Cited by 268
Self-citationReich, K., Pinter, A., Lacour, J. P., Ferrandiz, C., Micali, G., French, L. E., Lomaga, M., Dutronc, Y., Henneges, C., Wilhelm, S., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15666 · Cited by 192
Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K. B., Ferris, L. K., Langley, R. G., Tada, Y., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18851 · Cited by 175
Self-citationBai, F., Li, G. G., Liu, Q., Niu, X., Li, R., & Ma, H. (2019) · Journal of Immunology Research · doi:10.1155/2019/2546161 · Cited by 174
Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
Amin, M., No, D. J., Egeberg, A., & Wu, J. J. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0328-3 · Cited by 83
Self-citation
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“A thorough investigation later revealed there was no causal link between Brodalumab and suicidal behaviors (74).”
BackgroundZafiriou, E., Daponte, A., Siokas, V., Tsigalou, C., Dardiotis, E., & Bogdanos, D. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699848 · Cited by 81
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
Eshwar, V., Kamath, A., Shastry, R., Shenoy, A. K., & Kamath, P. (2022) · Pharmaceuticals · doi:10.3390/ph15111365 · Cited by 64
Wang, J., Wang, C., Liu, L., Hong, S., Ru, Y., Sun, X., Chen, J., Zhang, M., Lin, N., Li, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.993057 · Cited by 52
Rompoti, N., Politou, M., Stefanaki, I., Vavouli, C., Papoutsaki, M., Neofotistou, A., Rigopoulos, D., Stratigos, A., & Nicolaidou, E. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18825 · Cited by 36
Metadata
- Authors
- Lebwohl, M., Leonardi, C., Wu, J. J., Armstrong, A., Rawnsley, N., Merchant, M., Alexander, B., & Jacobson, A.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Saint Louis University (US)
- Dermatology Research and Education Foundation (US)
- University of Southern California (US)
- Bausch Health (United States) (US)
- Corresponding author
- Lebwohl, Mark
- Venue
- Dermatology and Therapy
- Published
- 2020-12-18
- Volume
- 11
- Issue
- 1
- Pages
- 173-180
- ISSN
- 2190-9172 (ISSN-L)
- 2193-8210
- PMC
- PMC7859129
- OpenAlex
- W3113634853
- Cited by
- 24
- References
- 16
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 3
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Dermatology and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Ortho Dermatologics
- Bausch Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- brodalumab, pharmacovigilance, adverse drug reactions, plaque psoriasis, suicide risk, psoriasis flare, joint pain, serious infections, Crohn's disease, cancer, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two-Year US Pharmacovigilance Report on Brodalumab. https://app.cochat.ai/papers/10.1007/s13555-020-00472-x
- The paper
- Lebwohl, M., Leonardi, C., Wu, J. J., Armstrong, A., Rawnsley, N., Merchant, M., Alexander, B., & Jacobson, A. (2021). Two-Year US Pharmacovigilance Report on Brodalumab. Dermatology and Therapy. https://doi.org/10.1007/s13555-020-00472-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
